What is CAR T‑cell therapy and how is it administered?

What is CAR T-Cell Therapy and How is it Administered?

CAR T-cell therapy is a personalized immunotherapy where a patient's own T lymphocytes are collected via leukapheresis, genetically engineered to express chimeric antigen receptors targeting tumor antigens, expanded ex vivo, and then reinfused after lymphodepleting chemotherapy to attack cancer cells. 1

What CAR T-Cell Therapy Is

CAR T-cell therapy represents a "living drug" that genetically modifies T cells to express a synthetic receptor comprising three key domains: an antigen-recognition domain (typically from a monoclonal antibody), intracellular signaling domains, and co-stimulatory domains 2. These engineered cells recognize tumor-associated antigens independently of MHC presentation, circumventing a major limitation of natural immune surveillance 3.

The therapy is FDA-approved for six hematologic malignancies: B-cell acute lymphoblastic leukemia, large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma 4. Most current products target CD19 on B-cell malignancies or BCMA for multiple myeloma 1.

How CAR T-Cell Therapy is Administered: Step-by-Step Process

1. Patient Selection and Pre-Leukapheresis Work-Up

• No age limit should be applied; decisions should be based on physical condition rather than chronological age 1
• Viral serology testing and compliance with EU Tissue and Cell Directives (2004/23/EC; 2006/17/EC; 2006/86/EC) are mandatory 1
• Complete pre-leukapheresis checklist including washout periods for prior therapeutics 1
• Infectious disease markers must be tested within 30 days of leukapheresis 1

2. Leukapheresis (T-Cell Collection)

• Facility requirements: FACT-JACIE accreditation is recommended for CAR-T delivery sites 1
• Non-mobilized leukapheresis is coordinated with the manufacturing facility via proprietary web-based platforms 1
• Minimum lymphocyte threshold: Absolute lymphocyte count (ALC) of 0.2 × 10⁹/L is generally recommended, though emerging evidence supports collection even with lower ALC in pediatric and adult patients 1
• Fresh leukapheresis products are stored at 2-8°C before shipping; Novartis accepts locally cryopreserved material within 30 months 1
• The presence of leukemic blasts in the collection is acceptable to manufacturers 1

3. Manufacturing (Ex Vivo Genetic Engineering)

• Patient T cells undergo genetic modification via viral-based gene transfer (most common) or non-viral methods including DNA-based transposons, CRISPR/Cas9, or mRNA electroporation 5
• Cells are expanded in culture to achieve therapeutic doses
• Manufacturing typically takes 2-4 weeks depending on the product

4. Bridging Therapy (During Manufacturing)

• Patients may receive chemotherapy or other treatments to control disease burden while awaiting CAR-T product
• Pre-emptive leukapheresis before extensive chemotherapy is feasible, as chemotherapy causes qualitative T-cell damage 1

5. Lymphodepleting Chemotherapy

• Administered 2-7 days before CAR-T infusion to create a favorable environment for CAR-T expansion 2
• Typically consists of fludarabine and cyclophosphamide

6. CAR-T Cell Infusion

• Thawed CAR-T cells are infused intravenously as a single treatment
• Each patient has only one opportunity to receive CAR-T therapy, making optimal timing critical 6
• Patients must remain within proximity of the treatment center for monitoring

7. Post-Infusion Monitoring and Management

Critical toxicities requiring close monitoring:

• Cytokine release syndrome (CRS): Occurs in 40-95% of patients, characterized by fever, hypotension, and multi-organ dysfunction 4
• Immune effector cell-associated neurotoxicity syndrome (ICANS): Occurs in 15-65% of patients 4
• Delayed toxicities: Pancytopenia, hypogammaglobulinemia requiring long-term follow-up and supportive care 2

Nursing staff must closely monitor and grade these toxicities for early intervention 2.

Clinical Efficacy

The therapy has demonstrated remarkable outcomes in hematologic malignancies:

• Large B-cell lymphoma: 4-year overall survival of 54.6% vs 46.0% with standard chemotherapy/transplant 4
• Pediatric ALL: 48% of patients alive and relapse-free at 3-year follow-up 4
• Multiple myeloma: Progression-free survival of 13.3 months vs 4.4 months with standard therapy 4
• B-ALL: Complete remission rates up to 92% in end-stage patients 5

Key Logistical Considerations

Common pitfalls to avoid:

• Delaying referral until disease is too advanced—early coordination between local hospitals and treatment centers is essential 6
• Inadequate patient education about safety/toxicity concerns (31.7% of physicians report patient concerns) and cost/insurance coverage (39.7% report concerns) 7
• Insufficient educational materials at clinic visits—73% of physicians never/rarely have materials available 7

The entire treatment sequence must be designed comprehensively, including pre- and post-CAR-T therapy planning, to optimize clinical outcomes 6. Multidisciplinary collaboration involving hematologists/oncologists, nurses, pharmacists, and administrators is essential throughout the process 1.